Brief: AB Science Receives Regulatory Authorization To Commence Second Phase 2 Covid-19 Study
28/09/2021 18:28
Sept 28 (Reuters) - AB SCIENCE SA ABS.PA :
* REG-AB SCIENCE RECEIVES REGULATORY AUTHORIZATION TO
COMMENCE A
SECOND PHASE 2 COVID-19 STUDY
* AB SCIENCE SA - STUDY DESIGN FOCUSES DIRECTLY ON
MASITINIB'S
ANTIVIRAL ACTIVITY AGAINST COVID-19 VIRUS (SARS-COV-2) FOR
TREATMENT OF PATIENTS AT AN EARLY STAGE OF DISEASE
* AB SCIENCE SA - WITH TWO PHASE 2 STUDIES, MASITINIB IS A
LEADING
CANDIDATE IN DEVELOPMENT OF ORAL PROTEASE INHIBITORS FOR
TREATMENT OF NON-HOSPITALIZED AND HOSPITALIZED COVID-19 PATIENTS
Source text for Eikon: ID:nGNE35jSzG
Further company coverage: ABS.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on AB Science SA
See all newsBrief: AB Science Temporarily Halts Europe Clinical Trials Ahead Of Strategic Reorganization
Brief: AB Science Says FDA Granted Status Of Minor Use In Major Species For Masivet
Brief: AB Science Says Co Received Japanese Patent Protection To Use Masitinib In Progressive MS Until 2041
Brief: AB Science Phase 1 AML Study Of AB8939 Shows 100% Partial Response Rate
Brief: AB Science Receives Notice Of Allowance For European Patent Covering Masitinib Until 2040 In Treatment Of Sickle Cell Disease